The Wall Street Journal95d agoneutral
Health Care Roundup: Market TalkFind insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
40last 24h
1802last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
The Wall Street Journal95d agoneutral
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-UpU.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
The Wall Street Journal95d agoneutral
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-UpU.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
MarketBeat98d agoneutral
Xenon Pharmaceuticals Q1 Earnings Call HighlightsXenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q